TY - JOUR
T1 - Regional lymph node recurrence after stereotactic body radiation therapy for lung cancer
T2 - Patterns of recurrence, treatment approaches, and clinical outcomes (KROG 21-09)
AU - Lee, Tae Hoon
AU - Shin, Hyunju
AU - Ahn, Yong Chan
AU - Kang, Min Kyu
AU - Song, Changhoon
AU - Kim, Woo Chul
AU - Moon, Sung Ho
AU - Kim, Jin Hee
AU - Cho, Jaeho
AU - Park, Hae Jin
AU - Lee, Heui Kwan
AU - Kim, Byoung Hyuck
AU - Kim, Hak Jae
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/6
Y1 - 2023/6
N2 - Purpose: To present the multi-institutional data on patterns of recurrence, treatment approaches, and clinical outcomes for regional lymph node (LN) recurrence after stereotactic body radiation therapy (SBRT) for primary lung cancer. Materials and Methods: The medical records of 114 patients who experienced regional LN recurrence as the first recurrence after lung SBRT were retrospectively reviewed. Patterns of recurrence were classified as local recurrence, regional recurrence, and distant metastasis. Clinical outcomes including progression-free survival (PFS) and overall survival (OS) were analyzed. Results: Half of the patients had regional LN recurrence only. The most common simultaneous recurrence was distant metastasis (38.6 %). Common sites of regional recurrence were ipsilateral hilar (47.2 %), ipsilateral upper mediastinal (40.6 %), and subcarinal (42.5 %) LN stations. 24 (21.1 %) patients underwent salvage radiation therapy (RT), and 44 (38.6 %) patients underwent palliative treatment. Better OS was observed in the salvage RT group (p = 0.025). The 1-year PFS and OS rates were 27.7 % and 55.2 %, respectively, with salvage RT, 14.0 % and 39.9 %, respectively, with palliative treatment, and 22.8 % and 26.8 %, respectively, with no additional treatment. Multivariate analysis showed that salvage RT (PFS, HR 0.463, p = 0.050; OS, HR 0.312, p = 0.002), palliative treatment (PFS, HR 0.436, p = 0.013; OS, HR 0.553, p = 0.050), and simultaneous distant metastasis (PFS, HR 2.335, p = 0.005; OS, HR 1.726, p = 0.054) affected clinical outcomes. Conclusion: Many cases of regional LN recurrence are confined to the locoregional area of patients, and appropriate treatment can improve the prognosis of these patients.
AB - Purpose: To present the multi-institutional data on patterns of recurrence, treatment approaches, and clinical outcomes for regional lymph node (LN) recurrence after stereotactic body radiation therapy (SBRT) for primary lung cancer. Materials and Methods: The medical records of 114 patients who experienced regional LN recurrence as the first recurrence after lung SBRT were retrospectively reviewed. Patterns of recurrence were classified as local recurrence, regional recurrence, and distant metastasis. Clinical outcomes including progression-free survival (PFS) and overall survival (OS) were analyzed. Results: Half of the patients had regional LN recurrence only. The most common simultaneous recurrence was distant metastasis (38.6 %). Common sites of regional recurrence were ipsilateral hilar (47.2 %), ipsilateral upper mediastinal (40.6 %), and subcarinal (42.5 %) LN stations. 24 (21.1 %) patients underwent salvage radiation therapy (RT), and 44 (38.6 %) patients underwent palliative treatment. Better OS was observed in the salvage RT group (p = 0.025). The 1-year PFS and OS rates were 27.7 % and 55.2 %, respectively, with salvage RT, 14.0 % and 39.9 %, respectively, with palliative treatment, and 22.8 % and 26.8 %, respectively, with no additional treatment. Multivariate analysis showed that salvage RT (PFS, HR 0.463, p = 0.050; OS, HR 0.312, p = 0.002), palliative treatment (PFS, HR 0.436, p = 0.013; OS, HR 0.553, p = 0.050), and simultaneous distant metastasis (PFS, HR 2.335, p = 0.005; OS, HR 1.726, p = 0.054) affected clinical outcomes. Conclusion: Many cases of regional LN recurrence are confined to the locoregional area of patients, and appropriate treatment can improve the prognosis of these patients.
KW - Lung cancer
KW - Lymphatic metastasis
KW - Salvage therapy
KW - Stereotactic body radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85149241463&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2023.109572
DO - 10.1016/j.radonc.2023.109572
M3 - Article
C2 - 36822359
AN - SCOPUS:85149241463
SN - 0167-8140
VL - 183
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
M1 - 109572
ER -